Importance to Know the Long-Term Outcome after Endovascular Therapy with Bare Metal Stent Implantation for Femoropopliteal Artery Disease.
作者信息
Ito Naruhiko
机构信息
Division of Cardiology, Yokosuka Kyosai Hospital.
出版信息
J Atheroscler Thromb. 2022 Oct 1;29(10):1423-1424. doi: 10.5551/jat.ED194. Epub 2022 Mar 3.
Abstract
摘要
相似文献
1
Importance to Know the Long-Term Outcome after Endovascular Therapy with Bare Metal Stent Implantation for Femoropopliteal Artery Disease.
J Atheroscler Thromb. 2022 Oct 1;29(10):1423-1424. doi: 10.5551/jat.ED194. Epub 2022 Mar 3.
2
The endovascular approach for in-stent restenosis in femoropopliteal disease.
Expert Rev Cardiovasc Ther. 2015 Apr;13(4):391-401. doi: 10.1586/14779072.2015.1023293. Epub 2015 Mar 11.
3
Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis.
Ann Vasc Surg. 2018 Jul;50:96-105. doi: 10.1016/j.avsg.2017.12.003. Epub 2018 Mar 4.
4
Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
J Vasc Surg. 2021 Jun;73(6):1998-2008.e1. doi: 10.1016/j.jvs.2020.12.061. Epub 2021 Jan 5.
5
Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
J Am Coll Cardiol. 2013 Oct 8;62(15):1320-7. doi: 10.1016/j.jacc.2013.05.079. Epub 2013 Jul 10.
6
Venous outcomes at 1 year after using the femoral vein as a conduit for passage of percutaneous femoropopliteal bypass.
J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1266-1272.e3. doi: 10.1016/j.jvsv.2020.12.080. Epub 2021 Jan 8.
7
Comparison Between Interwoven Nitinol and Drug Eluting Stents for Endovascular Treatment of Femoropopliteal Artery Disease.
Eur J Vasc Endovasc Surg. 2019 Dec;58(6):865-873. doi: 10.1016/j.ejvs.2019.09.002. Epub 2019 Oct 25.
8
Meta-Analysis Comparing Endovascular Treatment Modalities for Femoropopliteal Peripheral Artery Disease.
Am J Cardiol. 2020 Aug 1;128:181-188. doi: 10.1016/j.amjcard.2020.05.015. Epub 2020 May 16.
9
Long-term results of the heparin-bonded Viabahn stent graft in femoropopliteal TASC C and D lesions with a covered stent length of minimum 25 cm.
Vascular. 2019 Oct;27(5):553-559. doi: 10.1177/1708538119840863. Epub 2019 Mar 27.
10
[Endovascular treatment of femoropopliteal arterial occlusive disease].
Rev Med Liege. 2020 Nov;75(11):717-723.
本文引用的文献
1
Ten-Year Clinical Follow-Up Following Bare-Nitinol Stent Implantation for Femoropopliteal Artery Disease.
J Atheroscler Thromb. 2022 Oct 1;29(10):1448-1457. doi: 10.5551/jat.63225. Epub 2021 Dec 14.
2
Angiographic flow velocity predicts lower limb outcomes after endovascular therapy: Application of the frame count method.
Vasc Med. 2022 Feb;27(1):39-46. doi: 10.1177/1358863X211025613. Epub 2021 Jul 21.
3
1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon.
JACC Cardiovasc Interv. 2021 May 24;14(10):1123-1133. doi: 10.1016/j.jcin.2021.03.021.
4
Pathology and Multimodality Imaging of Acute and Chronic Femoral Stenting in Humans.
JACC Cardiovasc Interv. 2020 Feb 24;13(4):418-427. doi: 10.1016/j.jcin.2019.10.060.
5
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1. Epub 2018 Sep 24.
6
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Circulation. 2016 Apr 12;133(15):1472-83; discussion 1483. doi: 10.1161/CIRCULATIONAHA.115.016900. Epub 2016 Mar 11.
7
Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
J Am Coll Cardiol. 2015 Dec 1;66(21):2329-2338. doi: 10.1016/j.jacc.2015.09.063. Epub 2015 Oct 14.
8
Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial.
Circulation. 2015 Dec 8;132(23):2230-6. doi: 10.1161/CIRCULATIONAHA.115.017364. Epub 2015 Oct 7.
9
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24.
10
Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation.
Eur Heart J Cardiovasc Imaging. 2015 Oct;16(10):1101-11. doi: 10.1093/ehjci/jev031. Epub 2015 Mar 9.
Zotero 插件